Skip to content
10-K

Annual Report

Unicycive Therapeutics, Inc. UNCY

0001213900-26-035903

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 30, 2026 25.24M sh
Shares Diluted FY 2025 · Dec 31, 2025 15.89M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 6.7M sh
Capex FY 2025 · Dec 31, 2025 $24K
Capex FY 2025 · Dec 31, 2024 $72K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$31.32M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$28.58M
Cash And Equivalents FY 2025 · Dec 31, 2025 $29.2M
Cash And Equivalents FY 2025 · Dec 31, 2024 $26.14M
Stockholders Equity FY 2025 · Dec 31, 2025 $30.2M
Stockholders Equity FY 2025 · Dec 31, 2024 $7.43M
Stockholders Equity FY 2025 · Dec 31, 2023 −$3.81M
Current Liabilities FY 2025 · Dec 31, 2025 $18.94M
Current Liabilities FY 2025 · Dec 31, 2024 $24.12M
Total Liabilities FY 2025 · Dec 31, 2025 $18.94M
Total Liabilities FY 2025 · Dec 31, 2024 $24.24M
Current Assets FY 2025 · Dec 31, 2025 $48.96M
Current Assets FY 2025 · Dec 31, 2024 $30.95M
Total Assets FY 2025 · Dec 31, 2025 $49.14M
Total Assets FY 2025 · Dec 31, 2024 $31.67M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.67
Eps Diluted restated FY 2025 · Dec 31, 2024 −$5.65
Eps Basic FY 2025 · Dec 31, 2025 −$1.67
Eps Basic restated FY 2025 · Dec 31, 2024 −$5.65
Rd Expense FY 2025 · Dec 31, 2025 $9.12M
Rd Expense FY 2025 · Dec 31, 2024 $20.01M
Net Income FY 2025 · Dec 31, 2025 −$26.56M
Net Income FY 2025 · Dec 31, 2024 −$36.73M
Operating Income FY 2025 · Dec 31, 2025 −$29.52M
Operating Income FY 2025 · Dec 31, 2024 −$32.12M
Dividends Paid FY 2025 · Dec 31, 2024 $1.1M